JYJi’e Yang

Ji’e Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ji’e Yang has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Chenguang Li

    Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Disease, Shanghai, China; National Clinical Research Center for Interventional Medicine, Shanghai, China; State Key Laboratory of Cardiovascular Disease, Zhongshan Hospital, Fudan University, Shanghai, China; NHC Key Laboratory of Ischemia Heart Disease, Shanghai, China; Key Laboratory of Viral Heart Disease, Chinese Academy of Medical Science, Shanghai, China

    2 shared publications
  • Feng Zhang

    Department of Cardiology, Zhongshan Hospital, Fudan University; Shanghai, PR China; and

    2 shared publications
  • Junbo Ge

    Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases

    2 shared publications
  • Juying Qian

    Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China

    2 shared publications
  • Yang Gao

    Department of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, China

    2 shared publications
  • Ya’nAn Qu

    Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China

    2 shared publications

Latest Publications

  • Open Access

    Gender-Related Differences in Clinical Characteristics and Outcomes of Premature Coronary Artery Disease: Insight from the FOCUS Registry

    by Ya’nAn Qu, Ji’e Yang, Feng Zhang, Chenguang Li, Yuxiang Dai, Hongbo Yang, Yang Gao, Yueyi Pan, Kang Yao, Dong Huang, et al.

    Introduction. Although coronary artery disease (CAD) presentations and clinical outcomes differ by sex, little is known about premature CAD (PCAD). The present analysis aimed to evaluate the gender-related differences of PCAD in an Asian population from the FOCUS registry. Methods. A total of 1397 Asian young patients with angiographically confirmed CAD undergoing drug-eluting stent implantation were included in this analysis and divided into two groups according to the genders. Patients were followed up for three years and clinical outcomes were compared between groups. Results. Young women were older and more likely to have hypertension and diabetes than men (all p pp0.05). Conclusion. Despite remarkable differences in clinical characteristics between Asian males and females with PCAD, the two groups did not differ significantly in clinical outcomes.


  • Open Access

    Optimal strategy of primary percutaneous coronary intervention for acute myocardial infarction due to unprotected left main coronary artery occlusion (OPTIMAL): study protocol for a randomised controlled trial

    by for the OPTIMAL trial investigators, Yang Gao, Feng Zhang, Chenguang Li, Yuxiang Dai, Ji’e Yang, Ya’nan Qu, Juying Qian, Junbo Ge

    Primary percutaneous coronary intervention (PCI) for patients presenting with acute myocardial infarction (AMI) caused by left main coronary artery occlusion is associated with significantly higher mortality and risks of major adverse cardiovascular events. Deferred stent implantation may improve prognosis of primary PCI by reducing distal embolization and no-reflow phenomenon. There is no randomized clinical trial focusing on the effect and outcome of deferred stent implantation on primary PCI for left main coronary artery occlusion in contrast with conventional strategy. The Optimal Strategy of Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction due to Unprotected Left Main Coronary Artery Occlusion (OPTIMAL) study (ClinicalTrials.gov Identifier: NCT03282773) is an open-label, randomized, multicenter clinical trial in which 480 patients presenting with AMI caused by left main coronary artery occlusion recruited from 30 hospitals in mainland China will be randomly assigned 1:1 to immediate stenting or deferred stenting (scheduled 4–10 days after primary angioplasty) groups. The primary endpoint is a composite of all-cause mortality or recurrent myocardial infarction at 30 days after randomization. The secondary outcomes include all-cause mortality, cardiac death, recurrent myocardial infarction, and unplanned target vessel revascularization at 30 days, 6 months, and 12 months. The OPTIMAL study is designed to compare the clinical performance of deferred stenting with that of immediate stenting for AMI caused by left main coronary artery occlusion. ClinicalTrials.gov Identifier: NCT03282773 . Registered on 10 September 2017.